biostudies-literatureMeeus FVUB strategic research programFund Paul De KnopEutopiaFonds Wetenschappelijk OnderzoekThe Koning Boudewijn Stichting - Fund Catharina WeekersThe Scientific Fund Willy Geptse009110https://www.ebi.ac.uk/biostudies/studies/S-EPMC11575280biostudies-literatureUnknown12(11)<h4>Background</h4>Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblastoma cells but not on healthy brain tissue. Nanobody-based (nano)CARs are gaining increasing attention as promising alternatives to classical single-chain variable fragment-based (scFv)CARs, because of their single-domain nature and low immunogenicity. Still, B7-H3 nanoCAR-T cells have not been extensively studied in glioblastoma.<h4>Methods</h4>B7-H3 nanoCAR- and scFvCAR-T cells were developed and evaluated in human glioblastoma models. NanoCAR-T cells targeting an irrelevant antigen served as control. T cell activation, cytokine secreJournal for immunotherapy of cancerPreclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.PMC11575280OZR3808BOFG028220NN/A2022-J1811380-E0031SB9724N400075551S61023N8350841S68523N1S05020NZeven KAwad RMTuyaerts SVan Riet IMeeus FAutaers DDe Vlaeminck YGoyvaerts CDevoogdt NDe Becker ANeyns BFuneh CNBreckpot KfalsePreclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.<h4>Background</h4>Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblastoma cells but not on healthy brain tissue. Nanobody-based (nano)CARs are gaining increasing attention as promising alternatives to classical single-chain variable fragment-based (scFv)CARs, because of their single-domain nature and low immunogenicity. Still, B7-H3 nanoCAR-T cells have not been extensively studied in glioblastoma.<h4>Methods</h4>B7-H3 nanoCAR- and scFvCAR-T cells were developed and evaluated in human glioblastoma models. NanoCAR-T cells targeting an irrelevant antigen served as control. T cell activation, cytokine secre2024-01-01T00:00:00Z2024 Nov2025-04-04T20:38:58.686Z2025-04-04T20:38:58.686ZS-EPMC115752803956200510.1136/jitc-2024-009110